Intraarterial Peptide Receptor Radionuclide Therapy Using 90 Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.

MLA

Lawhn-Heath, Courtney, et al. “Intraarterial Peptide Receptor Radionuclide Therapy Using 90 Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 62, no. 2, Feb. 2021, pp. 221–27. EBSCOhost, https://doi.org/10.2967/jnumed.119.241273.

APA

Lawhn-Heath, C., Fidelman, N., Chee, B., Jivan, S., Armstrong, E., Zhang, L., Lindsay, S., Bergsland, E. K., & Hope, T. A. (2021). Intraarterial Peptide Receptor Radionuclide Therapy Using 90 Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 62(2), 221–227. https://doi.org/10.2967/jnumed.119.241273

Chicago

Lawhn-Heath, Courtney, Nicholas Fidelman, Bryant Chee, Salma Jivan, Evan Armstrong, Li Zhang, Sheila Lindsay, Emily K Bergsland, and Thomas A Hope. 2021. “Intraarterial Peptide Receptor Radionuclide Therapy Using 90 Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 62 (2): 221–27. doi:10.2967/jnumed.119.241273.